Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter sub-study of the EMPA-Heart CardioLink-6 Randomised Trial
Discrimination between normal and abnormal electrocardiograms: agreement of seven built-in automatic diagnostic programs in a cohort of >2000 12-lead traces.
Speaker:
Associate Professor I. Diemberger (Bologna, IT)